Danicamtiv vs Omecamtiv mecarbil

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Cardiac myosin (activator) · full Heart Failure pipeline

Danicamtiv

Developed by Kardigan under a licence from Bristol-Myers Squibb

Phase 2/3 in Heart Failuresmall molecule
Weak signal

NCT03447990 · Phase 1/2 · completed

This study was a randomized, quadruple-blind, placebo-controlled phase 1/2 dose-escalation trial in 52 patients, but it was designed to assess safety, tolerability, PK, and pharmacodynamic signals rather than to test a clinical efficacy hypothesis. The primary outcome measures are descriptive safety endpoints with no reported statistical comparisons, and the sample size is small, so despite the sound blinding and control the evidence for danicamtiv is limited. Secondary echocardiographic findings were analyzed by plasma-concentration ranges and are exploratory rather than confirmatory. Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose to 30 days post last dose (Up to 2 months)); Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts (Baseline, day 1-16, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose); Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - MAD Cohorts (Baseline, Day 1-16, 2 hours pre-dose and at 7-, 24-, and 48-hours post final dose); Mean Change From Baseline in Vital Signs Part 1 - SAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 1 - MAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 2 - SAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 2 - MAD Cohorts (Baseline and at 6-hours post-dose); Number of Participants With a Troponin I Increase - SAD Cohorts (Baseline, day 1-3, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose); Number of Participants With a Troponin I Increase - MAD Cohorts (Baseline, pre-dose and 7hr post dose on treatment day 1, day 2, day 5 and pre-dose and at 7-, 24-, and 48-hours post final dose); Number of Participants With Clinically Significant Laboratory Abnormalities (From first dose to 30 days post last dose (Up to 2 months)); Number of Participants With Clinically Significant Physical Examinations Abnormalities (From first dose to 30 days post last dose (Up to 2 months)): Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts. (not_applicable)

Result source: NCT03447990

Omecamtiv mecarbil

Developed by Cytokinetics and partners

Phase 3 in Heart Failuresmall molecule
Reliable signal

NCT02929329 · Phase 3 · completed

This was a large, randomized, triple-blind, placebo-controlled trial involving 8,256 participants. Its hard clinical primary endpoint—time to cardiovascular death or first heart-failure event—was met, favoring omecamtiv mecarbil (hazard ratio 0.92, p=0.0252).

Next expected readout: September 2027 · NCT06736574 (registry estimate)

Reported efficacy

Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1% (met)

Result source: NCT02929329

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDanicamtivOmecamtiv mecarbil
CV death or HF hospitalisation—Not reported37% vs 39.1%−2.1 vs placebon 4120NCT02929329
HF hospitalisation—Not reported27.7% vs 28.7%−1 vs placebon 4120NCT02929329
CV death—Not reported19.6% vs 19.4%+0.2 vs placebon 4120NCT02929329
KCCQ clinical summary, change—Not reported—Trial running · NCT06736574

CV death or HF hospitalisation

Danicamtiv
—Not reported
Omecamtiv mecarbil
37% vs 39.1%−2.1 vs placebon 4120NCT02929329

HF hospitalisation

Danicamtiv
—Not reported
Omecamtiv mecarbil
27.7% vs 28.7%−1 vs placebon 4120NCT02929329

CV death

Danicamtiv
—Not reported
Omecamtiv mecarbil
19.6% vs 19.4%+0.2 vs placebon 4120NCT02929329

KCCQ clinical summary, change

Danicamtiv
—Not reported
Omecamtiv mecarbil
—Trial running · NCT06736574
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Danicamtiv
Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts. NCT03447990 · Phase 1/2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Danicamtiv: 2 of 4 rows · Omecamtiv mecarbil: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDanicamtivOmecamtiv mecarbil
Dropout rate
—500 mga
NCT03447990 · Phase 1/2
show 8 more results
—400 mg
NCT03447990 · Phase 1/2
—350 mg
NCT03447990 · Phase 1/2
—175 mg
NCT03447990 · Phase 1/2
—100 mg
NCT03447990 · Phase 1/2
—75 mg
NCT03447990 · Phase 1/2
—75 mg
NCT03447990 · Phase 1/2
—50 mg
NCT03447990 · Phase 1/2
—SAD Cohort 1 Danicamtiv Optional P
NCT03447990 · Phase 1/2
26.5%b
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
show 28 more results
11.4%
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
4.8%25 mg BID
NCT02695420 · Phase 2 · registry result, not featured evidence
0%25 mg to 37.5 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
0%25 mg to 50 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
0%50 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
8.3%50 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
0%50 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
9.1%25 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
0%25 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
0%25 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
3.3%25 mg
NCT01786512 · Phase 2 · registry result, not featured evidence
8.1%PK-based titration
NCT01786512 · Phase 2 · registry result, not featured evidence
0%MR 100 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
0%MR 50 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
9.1%IR 37.5 mg TID
NCT00941681 · Phase 2 · registry result, not featured evidence
—Cohort 1 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
—Cohort 2 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
—2.2 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.125 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—500 mga
NCT03447990 · Phase 1/2
show 8 more results
—400 mg
NCT03447990 · Phase 1/2
—350 mg
NCT03447990 · Phase 1/2
—175 mg
NCT03447990 · Phase 1/2
—100 mg
NCT03447990 · Phase 1/2
—75 mg
NCT03447990 · Phase 1/2
—75 mg
NCT03447990 · Phase 1/2
—50 mg
NCT03447990 · Phase 1/2
—SAD Cohort 1 Danicamtiv Optional P
NCT03447990 · Phase 1/2
—b
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
show 28 more results
6.5%
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
—25 mg BID
NCT02695420 · Phase 2 · registry result, not featured evidence
—25 mg to 37.5 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
—25 mg to 50 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
—50 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
—50 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
—50 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
—25 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
—25 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
—25 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01786512 · Phase 2 · registry result, not featured evidence
—PK-based titration
NCT01786512 · Phase 2 · registry result, not featured evidence
—MR 100 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
—MR 50 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
—IR 37.5 mg TID
NCT00941681 · Phase 2 · registry result, not featured evidence
—Cohort 1 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
—Cohort 2 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
—2.2 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
—0.125 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
Serious AEs
0%500 mga
NCT03447990 · Phase 1/2
show 8 more results
0%400 mg
NCT03447990 · Phase 1/2
0%350 mg
NCT03447990 · Phase 1/2
0%175 mg
NCT03447990 · Phase 1/2
0%100 mg
NCT03447990 · Phase 1/2
16.7%75 mg
NCT03447990 · Phase 1/2
0%75 mg
NCT03447990 · Phase 1/2
0%50 mg
NCT03447990 · Phase 1/2
0%SAD Cohort 1 Danicamtiv Optional P
NCT03447990 · Phase 1/2
57.7%b
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
show 28 more results
16.2%
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
19%25 mg BID
NCT02695420 · Phase 2 · registry result, not featured evidence
5.3%25 mg to 37.5 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
15%25 mg to 50 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
18.2%50 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
0%50 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
7.1%50 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
0%25 mg M-F1
NCT01786512 · Phase 2 · registry result, not featured evidence
7.1%25 mg M-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
0%25 mg SCT-F2
NCT01786512 · Phase 2 · registry result, not featured evidence
24%25 mg
NCT01786512 · Phase 2 · registry result, not featured evidence
21.9%PK-based titration
NCT01786512 · Phase 2 · registry result, not featured evidence
0%MR 100 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
0%MR 50 mg BID
NCT00941681 · Phase 2 · registry result, not featured evidence
9.1%IR 37.5 mg TID
NCT00941681 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
2.9%Cohort 2 Active Drug
NCT00682565 · Phase 2 · registry result, not featured evidence
100%2.2 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%0.75 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
5.6%0.5 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
5.6%0.25 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
0%0.125 mg/kg/hr
NCT00624442 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
500 mga
abdominal discomfort 0% (placebo 0%)
acute kidney injury 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
NCT03447990 · Phase 1/2
show 8 more results
400 mg
anaemia 25% (placebo 0%)
neck pain 25% (placebo 0%)
orthostatic hypotension 25% (placebo 0%)
NCT03447990 · Phase 1/2
350 mg
bursitis 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
hypomagnesaemia 12.5% (placebo 0%)
NCT03447990 · Phase 1/2
175 mg
blood creatinine increased 12.5% (placebo 0%)
dyspnoea 12.5% (placebo 0%)
fatigue 12.5% (placebo 0%)
NCT03447990 · Phase 1/2
100 mg
ventricular tachycardia 33.3% (placebo 0%)
arthropod bite 16.7% (placebo 0%)
blood creatinine increased 16.7% (placebo 0%)
NCT03447990 · Phase 1/2
75 mg
vessel puncture site haemorrhage 33.3% (placebo 0%)
acute kidney injury 16.7% (placebo 0%)
alanine aminotransferase increased 16.7% (placebo 0%)
NCT03447990 · Phase 1/2
75 mg
fatigue 22.2% (placebo 0%)
anaemia 11.1% (placebo 0%)
application site rash 11.1% (placebo 0%)
NCT03447990 · Phase 1/2
50 mg
dermatitis contact 22.2% (placebo 0%)
ventricular tachycardia 22.2% (placebo 0%)
abdominal discomfort 11.1% (placebo 0%)
NCT03447990 · Phase 1/2
cardiac discomfort 16.7% (placebo 0%)
dyspnoea 16.7% (placebo 0%)
troponin increased 16.7% (placebo 0%)
NCT03447990 · Phase 1/2
b
hypotension 6.7% (placebo 5.9%)
cardiac failure 6.5% (placebo 7.1%)
dyspnoea 6.1% (placebo 6.3%)
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
show 28 more results
dizziness 4.9% (placebo 5.5%)
fatigue 4.9% (placebo 4.4%)
diarrhoea 3.8% (placebo 4.4%)
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
25 mg BID
dehydration 9.5% (placebo 0%)
dermatitis 9.5% (placebo 0%)
influenza 9.5% (placebo 4.8%)
NCT02695420 · Phase 2 · registry result, not featured evidence
25 mg to 37.5 mg BID Target Dose
viral upper respiratory tract infection 21.1% (placebo 19%)
hypotension 10.5% (placebo 0%)
periodontitis 10.5% (placebo 0%)
NCT02695420 · Phase 2 · registry result, not featured evidence
25 mg to 50 mg BID Target Dose
viral upper respiratory tract infection 20% (placebo 19%)
arthralgia 10% (placebo 0%)
dizziness 10% (placebo 4.8%)
NCT02695420 · Phase 2 · registry result, not featured evidence
50 mg M-F1
headache 18.2% (placebo 0%)
muscle spasms 18.2% (placebo 0%)
abdominal pain 9.1% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
50 mg M-F2
asthenia 9.1% (placebo 0%)
nasal congestion 9.1% (placebo 9.1%)
pain in extremity 9.1% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
50 mg SCT-F2
abnormal faeces 7.1% (placebo 0%)
blood alkaline phosphatase increased 7.1% (placebo 0%)
flatulence 7.1% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
25 mg M-F1
asthenia 10% (placebo 0%)
asthma 10% (placebo 0%)
bundle branch block left 10% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
25 mg M-F2
asthenia 21.4% (placebo 0%)
carotid bruit 7.1% (placebo 0%)
headache 7.1% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
25 mg SCT-F2
headache 38.5% (placebo 0%)
dry mouth 7.7% (placebo 0%)
insomnia 7.7% (placebo 9.1%)
NCT01786512 · Phase 2 · registry result, not featured evidence
25 mg
fatigue 9.3% (placebo 0%)
dyspnoea 6% (placebo 0%)
dizziness 5.3% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
PK-based titration
dyspnoea 8.9% (placebo 0%)
dizziness 6.2% (placebo 0%)
fatigue 6.2% (placebo 0%)
NCT01786512 · Phase 2 · registry result, not featured evidence
MR 100 mg BID
influenza like illness 8.3%
ventricular extrasystoles 8.3%
NCT00941681 · Phase 2 · registry result, not featured evidence
MR 50 mg BID
influenza like illness 0%
ventricular extrasystoles 0%
NCT00941681 · Phase 2 · registry result, not featured evidence
IR 37.5 mg TID
influenza like illness 0%
ventricular extrasystoles 0%
NCT00941681 · Phase 2 · registry result, not featured evidence
hypotension 3.2% (placebo 0%)
infusion site pain 3.2% (placebo 3.4%)
dyspnea 0% (placebo 3.4%)
NCT00682565 · Phase 2 · registry result, not featured evidence
dyspnea 8.8% (placebo 3.4%)
ventricular extrasystoles 5.9% (placebo 0%)
hypotension 2.9% (placebo 0%)
NCT00682565 · Phase 2 · registry result, not featured evidence
2.2 mg/kg/hr
troponin increased 100% (placebo 0%)
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
NCT00624442 · Phase 2 · registry result, not featured evidence
1.0 mg/kg/hr
troponin increased 25% (placebo 0%)
sinus bradycardia 12.5% (placebo 0%)
constipation 0% (placebo 4.9%)
NCT00624442 · Phase 2 · registry result, not featured evidence
1.0 mg/kg/hr
dizziness postural 16.7% (placebo 0%)
hypotension 16.7% (placebo 0%)
orthostatic hypotension 16.7% (placebo 4.9%)
NCT00624442 · Phase 2 · registry result, not featured evidence
1.0 mg/kg/hr
somnolence 6.3% (placebo 2.4%)
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.75 mg/kg/hr
orthostatic hypotension 50% (placebo 4.9%)
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.75 mg/kg/hr
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
dyspnea 0% (placebo 2.4%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.5 mg/kg/hr
urinary tract infection 6.3% (placebo 2.4%)
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.5 mg/kg/hr
dizziness postural 5.6% (placebo 0%)
infusion site pain 5.6% (placebo 2.4%)
orthostatic hypotension 5.6% (placebo 4.9%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.25 mg/kg/hr
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
dyspnea 0% (placebo 2.4%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.25 mg/kg/hr
constipation 5.6% (placebo 4.9%)
dizziness postural 5.6% (placebo 0%)
dyspnea 5.6% (placebo 2.4%)
NCT00624442 · Phase 2 · registry result, not featured evidence
0.125 mg/kg/hr
musculoskeletal pain 12.5% (placebo 2.4%)
constipation 0% (placebo 4.9%)
dizziness postural 0% (placebo 0%)
NCT00624442 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 27 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Omecamtiv mecarbil

CV Death or HF Hospitalization Composite 37% (n=4120) vs 39.1% (n=4112) placebo
responder rate · % of participants
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
CV Death 19.6% (n=4120) vs 19.4% (n=4112) placebo
responder rate · % of participants
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
KCCQ-TSS 5.83 vs 6.29 placebo score @ 24wk
absolute change · score
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
show 1 more result
23.65 vs 6.29 placebo score @ 24wk
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
HF Hospitalization 27.7% (n=4120) vs 28.7% (n=4112) placebo
responder rate · % of participants
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
All-cause Mortality 25.9% (n=4120) vs 25.9% (n=4112) placebo
responder rate · % of participants
NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
Peak VO2 Change mL/Min -0.239 vs 0.207 placebo kg @ 20wk
absolute change · kg
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
Total Workload Change Watts -3.798 vs 1.59 placebo Watt @ 20wk
absolute change · Watt
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
Ventilatory Efficiency Change Slope 0.277 vs -0.138 placebo slope @ 20wk
absolute change · slope
NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3
Systolic Ejection Time Change Msec 20.5 vs -1.7 placebo msec @ 16wk25 mg BID
absolute change · msec
NCT02695420 · Phase 2 · registry result, not featured evidence
show 2 more results
27.6 vs -1.7 placebo msec @ 16wk25 mg to 37.5 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
23.8 vs -1.7 placebo msec @ 16wk25 mg to 50 mg BID Target Dose
NCT02695420 · Phase 2 · registry result, not featured evidence
Total Exercise Duration 41.5 vs 60.1 placebo seconds @ 0.14wk
ratio to baseline · seconds
NCT00682565 · Phase 2 · registry result, not featured evidence
show 1 more result
40.5 vs 60.1 placebo seconds @ 0.14wk
NCT00682565 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Danicamtiv's landscape · Omecamtiv mecarbil's landscape